NanoViricides, Inc.
135 Wood Street
Suite 205
West Haven
Connecticut
06516
United States
Website: http://www.nanoviricides.com/
Email: info@nanoviricides.com
310 articles with NanoViricides, Inc.
-
NanoViricides, Inc. Has Filed its Annual Report: Strengthened Financial Position and Rapidly Developing Novel Coronavirus Drug Program
10/15/2020
NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2020 with the Securities and Exchange Commission on Tuesday, October 12, 2020.
-
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19
9/16/2020
NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
-
NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference
9/4/2020
NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reported on the Presentation by Anil R. Diwan, Ph.D., its President and Executive Chairman, at the LD 500 investor conference yesterday, Thursday, September 3rd at 11:20 AM EDT.
-
NanoViricides, based in Shelton, Connecticut, outlined its approach to developing therapies against COVID-19 at the LD 500 investor conference yesterday.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
-
NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020
7/21/2020
NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that Anil R. Diwan, PhD, President and Executive Chairman of the Company, will participate in the "B. Riley FBR Virtual Infectious Disease Summit - Therapeutics Day" on Tuesday, July 21, 2020.
-
NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock
7/13/2020
NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that it has completed an underwritten public offering with gross proceeds of $11.5 million before deducting underwriting discounts and other estimated offering expenses.
-
NanoViricides Prices $10.0 Million Underwritten Public Offering of Common Stock
7/9/2020
NanoViricides, Inc. a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $10.0 million before deducting underwriting discounts and other estimated offering expenses.
-
Nanoviricides Commences Underwritten Public Offering of Common Stock
7/8/2020
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), today announced the commencement of an underwritten public offering.
-
Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides’ SARS-CoV-2 Therapeutics Program
7/8/2020
NanoViricides, Inc. a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that excellent safety and tolerability of the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases was observed in an animal model.
-
NanoViricides Announces Addition to Russell Microcap(R) Index
6/30/2020
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has been added to the Russell Microcap® Index effective after the U.S. markets opened yesterday, Monday, June 29, 2020.
-
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus
5/21/2020
NanoViricides, Inc. a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases.
-
NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split
9/12/2019
NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), announced today that its Board of Directors has approved a 1-for-20 reverse split of all of the Company's capital stock, including its common stock, which will be effective after the market closes on September 23, 2019.
-
NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND
8/26/2019
NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), reports that it has filed its annual report (Form 10-K) for the financial year ending June 30, 2019, with the Securities and Exchange Commission (SEC) on Friday, August 23, 2019.
-
NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials
8/5/2019
The Company reports that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment.
-
NanoViricides, Inc. Appoints Dr. Mark Day to its Board of Directors
6/10/2019
NanoViricides, Inc., a leader in developing novel nanomedicines to treat viral diseases, reports that Dr. Mark Day has been duly appointed as an Independent Director to its Board of Directors, effective June 6, 2019.
-
NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate
6/3/2019
NanoViricides, Inc. a company with novel platform technology to fulfill unmet medical needs in treating difficult and life-threatening viral diseases, reports that it has received favorable comments from the US FDA on the Company's pre-IND application for its lead drug candidate.
-
NanoViricides Files Quarterly Report for Period Ending March 31, 2019 - HerpeCide™ Drug Candidate Pre-IND Application Submitted, Progressing Towards Clinical Trials
5/20/2019
NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed its quarterly report for its third quarter of financial year 2019 in a timely manner with the Securities and Exchange Commission.
-
NanoViricides Announces Completion of Production of its Lead Candidate for Upcoming GLP Tox Package Studies
5/13/2019
NanoViricides, Inc. a company with novel platform technology to meet unmet medical needs in treating difficult and life-threatening viral diseases, reports that it has successfully completed manufacture of the drug for the upcoming GLP Safety/Toxicology study of its lead candidate in several kilogram quantities.